Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...

UC Riverside study may lead to new treatments for multiple sclerosis. Multiple sclerosis (MS) affects an estimated 2.3 ...

The Food and Drug Administration has granted Fast Track designation to AMX0114 for the treatment of amyotrophic lateral sclerosis (ALS).

SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

Multiple sclerosis (MS ... now sheds light on the underlying mechanisms of cerebellar degeneration in MS, suggesting that mitochondrial dysfunction may play a key role in the progressive loss of ...

Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in ...

Dr Johnathan Cooper-Knock from the University of Sheffield is one of eight outstanding scientists nationwide to receive the 2025 Lister Award from the ...